PainReform Ltd. (PRFX) News

PainReform Ltd. (PRFX): $0.49

0.03 (-5.38%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Filter PRFX News Items

PRFX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PRFX News From Around the Web

Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.

PainReform Provides Business Update for the Third Quarter of 2023

Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomyTEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter ended September 30, 2023. Ilan Hadar, Chief Executive Officer of PainReform, stated, "We are pleased to report a number of

Yahoo | November 15, 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second part of the Company’s phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery. Star

Yahoo | September 11, 2023

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryTEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Company has been selected for a poster presentation, titled “Pharmacokinetics and Safety P

Yahoo | September 7, 2023

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Mr. Hadar will be participating in one-

Yahoo | September 5, 2023

7 Stocks Under $10 to Buy for August

Stocks under $10 have many advantages, so it pays to see which has the best potential for growth.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | August 10, 2023

PainReform Provides Business Update for the Second Quarter of 2023

Targeting to commence second part of Phase 3 clinical trial in bunionectomy during the fourth quarter of 2023TEL AVIV, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the second quarter ended June 30, 2023. Ilan Hadar, Chief Executive Officer of PainReform, stated, “We are pleased to report conti

Yahoo | August 10, 2023

Dow On Track For 9 Straight After Johnson & Johnson Earnings

The Dow Jones Industrial Average is looking to extend its win streak, last seen up 250 points as it paces for its ninth consecutive win.

TalkMarkets.com | July 20, 2023

Why Is Discover Financial (DFS) Stock Down 13% Today?

Discover Financial (DFS) stock is falling on Thursday after the financial services company revealed it's undergoing a regulatory review.

William White on InvestorPlace | July 20, 2023

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

Eliem Therapeutics (ELYM) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives.

William White on InvestorPlace | July 20, 2023

Why Is PainReform (PRFX) Stock Up 38% Today?

PainReform (PRFX) stock is rallying on Thursday after the pharmaceutical company regained compliance with Nasdaq listing requirements.

William White on InvestorPlace | July 20, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!